MedTrace Logo

Convalescent Plasma for the Treatment of Severe SARS-CoV-2 (COVID-19)

NCT04391101 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 231

Last updated 2020-05-20

No results posted yet for this study

Summary

Convalescent plasma has been used for over 100 years in the treatment of severe acute respiratory infections of viral origin. There are not pharmacological treatments for the actual outbreak for SARS-Cov-2 and it is necessary to evaluate the efficacy of treatment options, including convalescent plasma transfusion. The hypothesis is that convalescent plasma is efficacious and safe for reducing mortality in patients with COVID-19 treated in ICU

Conditions

Interventions

DRUG

Convalescent plasma

400-500ml convalescent plasma

Sponsors & Collaborators

  • Clínica León XIII

    collaborator UNKNOWN

  • Grupo de Inmunodeficiencias primarias Universidad de Antioquia

    collaborator UNKNOWN

  • Clínica Universitaria Bolivariana

    collaborator UNKNOWN

  • Hospital Pablo Tobón Uribe

    collaborator OTHER

  • Clínica Rosario El Tesoro

    collaborator UNKNOWN

  • Clínica Las Américas

    collaborator UNKNOWN

  • Clínica Cardiovid

    collaborator UNKNOWN

  • Hospital San Vicente Fundación

    lead OTHER

Principal Investigators

  • Oliver Perilla Suarez, Hematologist · Hospital San Vicente Fundación

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-30
Primary Completion
2021-06-30
Completion
2021-12-31

Countries

  • Colombia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04391101 on ClinicalTrials.gov